Edesa Biotech Current Valuation vs. Shares Owned By Institutions

EDSA Stock  USD 1.94  0.14  7.78%   
Considering the key profitability indicators obtained from Edesa Biotech's historical financial statements, Edesa Biotech may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Edesa Biotech's ability to earn profits and add value for shareholders. At present, Edesa Biotech's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's Days Sales Outstanding is expected to grow to 92.27, whereas Sales General And Administrative To Revenue is forecasted to decline to 6.19. At present, Edesa Biotech's Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to 1,354, whereas Accumulated Other Comprehensive Income is projected to grow to (230.5 K).
For Edesa Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Edesa Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Edesa Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Edesa Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Edesa Biotech over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(19.78)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.72)
Return On Equity
(1.29)
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Edesa Biotech Shares Owned By Institutions vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth.
Edesa Biotech is rated below average in current valuation category among its peers. It is rated below average in shares owned by institutions category among its peers . The ratio of Current Valuation to Shares Owned By Institutions for Edesa Biotech is about  351,534 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.

Edesa Current Valuation vs. Competition

Edesa Biotech is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 339.01 Million. Edesa Biotech claims roughly 4.29 Million in current valuation contributing just under 2% to equities under Health Care industry.

Edesa Shares Owned By Institutions vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Edesa Biotech

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
4.29 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Edesa Biotech

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
12.19 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Edesa Shares Owned By Institutions Comparison

Edesa Biotech is currently under evaluation in shares owned by institutions category among its peers.

Edesa Biotech Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Edesa Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Edesa Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Edesa Biotech's change in net profit over the period of time. It can combine multiple indicators of Edesa Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-242.6 K-230.5 K
Operating Income-7 M-7.4 M
Income Before Tax-6.2 M-6.5 M
Total Other Income Expense Net845.5 K887.8 K
Net Loss-6.2 M-6.5 M
Income Tax Expense 720.00  1,354 
Interest Income260.9 K273.9 K
Net Loss-15.8 M-15 M
Net Loss-7.5 M-7.9 M
Net Interest Income333.3 K350 K
Change To Netincome2.6 M2.7 M
Net Loss(1.93)(46.75)
Income Quality 0.79  0.51 
Net Income Per E B T 1.00  1.00 

Edesa Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Edesa Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Edesa Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Edesa Biotech's important profitability drivers and their relationship over time.

Use Edesa Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edesa Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edesa Biotech will appreciate offsetting losses from the drop in the long position's value.

Edesa Biotech Pair Trading

Edesa Biotech Pair Trading Analysis

The ability to find closely correlated positions to Edesa Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edesa Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edesa Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edesa Biotech to buy it.
The correlation of Edesa Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edesa Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edesa Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edesa Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Edesa Biotech position

In addition to having Edesa Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Recreation Thematic Idea Now

Recreation
Recreation Theme
Companies involved in production and services of recreational goods, foods, and accessories. The Recreation theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recreation Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:
Check out Investing Opportunities.
For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
To fully project Edesa Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Edesa Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential Edesa Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Edesa Biotech investors may work on each financial statement separately, they are all related. The changes in Edesa Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Edesa Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.